KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Research & Development (2016 - 2025)

Historic Research & Development for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $973.7 million.

  • Vertex Pharmaceuticals' Research & Development fell 250.33% to $973.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.9 billion, marking a year-over-year increase of 769.08%. This contributed to the annual value of $3.9 billion for FY2025, which is 769.08% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Research & Development stood at $973.7 million for Q4 2025, which was down 250.33% from $977.7 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Research & Development peaked at $998.7 million during Q4 2024, and registered a low of $448.7 million during Q2 2021.
  • Its 5-year average for Research & Development is $759.1 million, with a median of $787.4 million in 2023.
  • In the last 5 years, Vertex Pharmaceuticals' Research & Development tumbled by 536.92% in 2021 and then surged by 3811.56% in 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' Research & Development (Quarter) stood at $567.8 million in 2021, then grew by 22.24% to $694.1 million in 2022, then grew by 18.8% to $824.6 million in 2023, then rose by 21.11% to $998.7 million in 2024, then decreased by 2.5% to $973.7 million in 2025.
  • Its Research & Development was $973.7 million in Q4 2025, compared to $977.7 million in Q3 2025 and $978.4 million in Q2 2025.